Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research
More News: Anemia | Blood Transusion | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Conferences | Databases & Libraries | Diabetes | Dialysis | Endocrinology | General Medicine | Heart | Heart Attack | Heart Failure | Heart Transplant | Hypertension | Iron | Kidney Transplant | Kidney Transplantation | Oral Cancer | Pulmonary Hypertension | Stroke | Study | Transplant Surgery | Transplants | Urology & Nephrology